[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental Group: FINLAY-FR-2 + FINLAY-FR-1A. FINLAY-FR-2: 25 \u00b5g of RBD-TT; by intramuscular route; 0.5 mL; in scheme 0 - 28 days. FINLAY-FR-1A: 50 \u00b5g of d-RBD + Aluminum Hydroxide Gel; by intramuscular route; 0.5 mL as dose booster 56 days.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "25 \u00b5g+50 \u00b5g;2+1;Days0-28+day 56;IM", "treatment_id": 1519, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine+finlay-fr-2 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]